Elucid Names Kelly Huang as CEO
22 Julio 2024 - 6:04AM
Business Wire
Experienced commercial leader takes helm to
expand cardiovascular diagnostic company globally and commercialize
company’s flagship plaque analysis software
Elucid, a pioneering AI medical technology company providing
physicians with imaging analysis software based on ground truth
histology to support treatment of cardiovascular disease, has named
Kelly Huang, PhD, as president and chief executive officer (CEO).
The appointment comes as Elucid continues to prepare for
commercialization of its flagship plaque analysis software.
Elucid’s PlaqueIQ is the only FDA-cleared computed tomography
angiography (CTA) algorithm that objectively quantifies and
characterizes plaque validated against ground truth histology, the
gold standard for characterization of coronary plaques, as
indicated by renowned pathologists.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240722125314/en/
Elucid CEO Kelly Huang, PhD (Photo:
Business Wire)
Mr. Huang brings significant commercial experience and expertise
in market development of impactful medical products to Elucid.
Previously he served as chief operating officer (COO) for Cardea
Bio, the world’s only mass producer of biocompatible
semiconductors, which was acquired by Paragraf in 2023. Prior to
that, he held the positions of COO and head of Nutra-Theraputic at
L-Nutra, Inc. Before that, Mr. Huang was president, CEO and board
director at Obalon Therapeutics, a publicly traded medical device
company. He also held senior leadership roles at Nestle/Galderma,
Endo Pharmaceuticals, and Johnson & Johnson. Mr. Huang holds a
PhD in chemical engineering from Stanford University.
“Kelly brings a history of successful commercialization and
growth experience to Elucid at a critical time in the company’s
progression to commercial operations,” said Scott Huennekens,
executive chairman of Elucid’s board of directors. “His creativity
and prowess in market planning, physician engagement, and sales and
marketing will bolster the company’s go-to-market plans and help
ensure a successful commercial launch and growth of Elucid’s suite
of products in development.”
Mr. Huang’s appointment as CEO follows Elucid’s $80 million
Series C fundraise in Q4 2023, led by Elevage Medical Technologies,
which is intended to help further commercialization and expansion
plans. Elucid also moved into new headquarters last month as part
of its ramp up for commercial launch, which includes hiring
additional employees. As part of its launch plans, last year Elucid
made other critical additions to its leadership team, naming Windi
Hary as senior vice president (SVP) of regulatory affairs and
quality management, and Andrew Miller as chief technology officer.
Following Mr. Huang’s appointment, Blake Richards continues in a
leadership role at Elucid as COO.
“I am energized to lead Elucid at such an exciting and important
time, and I’m eager to help maximize the impact of its AI
technology to improve patient care and make a positive impact in
the field of cardiovascular disease management,” said Mr. Huang.
“The groundwork laid by the team to prepare for the company’s first
commercial launch is both extensive and impressive. I am grateful
to Blake for his dedication to Elucid and look forward to working
alongside him.”
Cardiovascular disease is the most common cause of death and
disability globally, largely driven by myocardial infarction and
ischemic stroke caused by atherosclerosis (plaque build-up and
rupture in the arteries).1 Elucid offers the first and only
histology-validated FDA-cleared software to non-invasively quantify
and characterize non-calcified plaque and its components such as
lipid-rich necrotic core (LRNC), giving potential insights into
high-risk vulnerable plaques, key drivers of risk of heart attack
and stroke.2 The company is also pursuing an indication for
non-invasive measurement of fractional flow reserve (FFRCT),
uniquely derived from its PlaqueIQ technology, to measure coronary
blockages and the extent of ischemia.
About Elucid
Elucid is a Boston-based AI medical technology company dedicated
to developing technology designed to help physicians better
understand the root cause of cardiovascular disease. Elucid’s
PlaqueIQ software is the only FDA-cleared computed tomography
angiography (CTA) algorithm that objectively quantifies plaque
morphology validated against ground truth histology, the gold
standard for characterization of coronary plaques, as indicated by
renowned pathologists. Elucid is also pursuing an indication for
FFRCT, derived from its plaque algorithm, to help identify coronary
blockages and the extent of ischemia non-invasively. PlaqueIQ
equips physicians with critical information regarding the type and
amount of plaque in arteries that can lead to heart attack and
stroke. For more information, visit elucid.com.
1 World Health Organization (WHO), Cardiovascular diseases
(CVDs) fact sheet. 2017 23, April 2020]; Available from:
https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds).
2 A. Hafiane, Vulnerable plaque, characteristics, detection, and
potential therapies, J. Cardiovasc. Dev. Dis. 6 (3) (2019).
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722125314/en/
Sam Choinski Pazanga Health Communications (860) 301-5058
schoinski@pazangahealth.com